mirvetuximab
ImmunoGen
['mirvetuximab', 'ovarian']
my takeaways from today's mirvetuximab study in ovarian cancer #asco23 and why it cannot be considered "standard of care"
1. os but no info on post-progression tx. global trial so may not be accessible. 2. only 35% of patients eligible since they need high fr-expression 
Geriatric Oncologist @incmnszmx #gerionc, Global Oncology. @ASCO BOD 20-24, FASCO. PhD @UNAM_MX Opinions my own. 🇲🇽 https://t.co/GruVowjxCI…